1-6 of 6
Christina Hadjiaggelidou
Close
Sort by
Journal Articles

No Survival Improvement for Central Nervous System Multiple Myeloma By the Use of Novel Anti-Myeloma Agents: The Greek Myeloma Study Group Experience

Eirini Katodritou, Evangelos Terpos, Sosana Delimpasi, Argiris Symeonidis, MD, Panagiotis Repousis, Marie-Christine Kyrtsonis, Eurydiki Michalis, Maria Papathanasiou, Genovefa Polychronidou, Christina Hadjiaggelidou, Alexandra Kouraklis, Ioannis Patsias, Maria Gavriatopoulou, Efstathios Kastritis, MD, Maria Kotsopoulou, Evgenia Verrou, Vassiliki Gastari, Evlambia Giannopoulou, Nikos Spyridis, Pavlina Konstantinidou, Anastasia Pouli, Achilles Anagnostopoulos, Meletios A. Dimopoulos
Journal: Blood
Blood (2014) 124 (21): 4752.
https://doi.org/10.1182/blood.V124.21.4752.4752
Published: 2014
Journal Articles

Clinical Features, Outcome and Prognostic Factors For Survival and Evolution To Multiple Myeloma Of Solitary Plasmacytomas: A Report Of The Greek Myeloma Study Group In 97 Patients

Eirini Katodritou, Evangelos Terpos, Argiris S. Symeonidis, Anastasia Pouli, Charikleia Kelaidi, Marie-Christine Kyrtsonis, MD, Maria Kotsopoulou, Sosana Delimpasi, Anna Christoforidou, Nikolaos Giannakoulas, Nora-Athina Viniou, Ekaterini Stefanoudaki, Christina Hadjiaggelidou, Dimitrios Christoulas, Evgenia Verrou, Vassiliki Gastari, Sofia Papadaki, Freideriki Patakiouta, Efstathios Kastritis, Alexandra Kouraklis, Pavlina Konstantinidou, Achilles Anagnostopoulos, Konstantinos Zervas, Meletios A. Dimopoulos, MD
Journal: Blood
Blood (2013) 122 (21): 3130.
https://doi.org/10.1182/blood.V122.21.3130.3130
Published: 2013
Journal Articles

Correlation of Erythropoietin Stimulating Agents (ESAs) with the Post-Therapy Micro-Vessel Density (MVD) in Newly Diagnosed Myeloma Patients: a Possible Mechanism of ESAs Association with Reduced Survival Rates.

Eirini Katodritou, Evangelos Terpos, Vassiliki Kaloutsi, Evgenia Verrou, Vassiliki Gastari, Maria Varthaliti, Christina Hadjiaggelidou, Evgenia Panousi, Sofia Georgiadou, Constantinos Hatjileontis, Nicos Konstantinou, Konstantinos Zervas
Journal: Blood
Blood (2009) 114 (22): 4873.
https://doi.org/10.1182/blood.V114.22.4873.4873
Published: 2009
Journal Articles

Thalidomide–Containing Regimens Induce Recovery of Normal Immunoglobulins in Newly Diagnosed Patients with Multiple Myeloma; Recovery of Normal Immunoglobulins Improves Survival.

Eirini Katodritou, MD, PhD, Evgenia Verrou, MD, Anastasia Banti, MD, Dimitra Mihou, MD, Vassiliki Gastari, MD, Christina Hadjiaggelidou, MD, Dimitra Markala, MD, Anna Lazaridou, MD, PhD, Evangelos Terpos, MD, PhD, Konstantinos Zervas, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 2738.
https://doi.org/10.1182/blood.V110.11.2738.2738
Published: 2007
Journal Articles

The Addition of Thalidomide in Any Line of Treatment of Multiple Myeloma, Improves Overall Survival: Single Center Experience in 246 Patients.

Eirini Katodritou, MD, PhD, Evgenia Verrou, MD, Anastasia Banti, MD, Vassiliki Gastari, MD, Dimitra Mihou, MD, Christina Hadjiaggelidou, MD, Dimitra Markala, MD, Anna Lazaridou, MD, PhD, Evangelos Terpos, MD, PhD, Konstantinos Zervas, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 4813.
https://doi.org/10.1182/blood.V110.11.4813.4813
Published: 2007
Journal Articles

Recombinant Human Erythropoietin May Negatively Influence Survival in Newly Diagnosed Patients with Multiple Myeloma: A Single Center Experience in 246 Patients.

Eirini Katodritou, MD, PhD, Evgenia Verrou, MD, Anastasia Banti, MD, Vassiliki Gastari, MD, Dimitra Mihou, MD, Christina Hadjiaggelidou, MD, Dimitra Markala, MD, Anna Lazaridou, MD, PhD, Evangelos Terpos, MD, PhD, Konstantinos Zervas, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 4814.
https://doi.org/10.1182/blood.V110.11.4814.4814
Published: 2007